Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + lenvatinib + gemcitabine + cisplatin
- Development stage
- Phase 2
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Hepatic Arterial Infusion
01
Overview
This combination therapy, referred to as the HAIC-quad regimen, is being investigated by West China Hospital as a first-line treatment for locally advanced or metastatic intrahepatic cholangiocarcinoma (ICC). It consists of hepatic arterial infusion chemotherapy (HAIC) using gemcitabine and cisplatin, combined with the immune checkpoint inhibitor durvalumab and the multikinase inhibitor lenvatinib. HAIC allows for high local concentrations of chemotherapeutic agents in the liver while minimizing systemic toxicity. Durvalumab targets the PD-L1 pathway to enhance anti-tumor immune responses, while lenvatinib inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor progression, including VEGFR and FGFR.
- Other names
- HAIC combined with durvalumab and lenvatinibHAIC-GemCis plus durvalumab and lenvatinib
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on durvalumab + lenvatinib + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + lenvatinib + gemcitabine + cisplatin.